Britain probing AstraZeneca-Alexion deal over competitors issues By Reuters


© Reuters. FILE PHOTO: A general view of the AstraZeneca site in Macclesfield, UK, May 11, 2021. REUTERS / Phil Noble

(Reuters) – Britain’s competition regulator announced Tuesday that it had launched an investigation into the $ 39 billion AstraZeneca (NASDAQ 🙂 acquisition of US drug maker Alexion (NASDAQ :), possibly to prevent competition on the UK market or elsewhere.

The competition and market regulator asked all interested parties to comment on the deal to help with the evaluation. A deadline of June 3rd was set for all parties to see it.

Anglo-Swedish drug maker AstraZeneca agreed to buy Alexion in December as part of its largest business to date and to move away from its fast-growing cancer business to focus on rare disease drugs and immunology.

Disclaimer: Fusion Media would like to remind you that the information contained on this website is not necessarily real-time or accurate. All CFDs (stocks, indices, futures) and forex prices are not provided by exchanges, but by market makers. Therefore, prices may not be accurate and may differ from the actual market price. This means that the prices are indicative and not suitable for trading purposes. Therefore, Fusion Media is not responsible for any trading losses you may incur as a result of using this data.

Fusion Media, or anyone involved with Fusion Media, assumes no liability for any loss or damage caused by reliance on the information contained on this website, such as data, offers, charts, and buy / sell signals. Please inform yourself comprehensively about the risks and costs associated with trading in the financial markets. This is one of the riskiest forms of investment possible.

Leave A Reply

Your email address will not be published.